Additional Measures After Stopping Nucleoside Analogues in HbeAg-Negative Chronic Hepatitis B: Better But Not Enough

被引：0
|
作者：
Lim, Seng gee [1 ,3 ]
Tan, Yong chuan [2 ]
机构：
[1] Natl Univ Singapore, Natl Univ Hlth Syst, Div Gastroenterol & Hepatol, Dept Med, Singapore, Singapore
[2] Natl Univ Hlth Syst, Div Gastroenterol & Hepatol, Dept Med, Singapore, Singapore
[3] Natl Univ Singapore Hosp, Dept Gastroenterol & Hepatol, 1E Lower Kent Ridge Rd, Singapore 119228, Singapore
来源：
GASTROENTEROLOGY | 2024年 / 166卷 / 01期
基金：
英国医学研究理事会;
关键词：
CESSATION; HBSAG;
D O I：
10.1053/j.gastro.2023.10.005
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：23 / 24
页数：2
相关论文
共 50 条
  • [21] Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues
    Dusheiko, Geoffrey
    LIVER INTERNATIONAL, 2013, 33 : 137 - 150
  • [22] INCREASE RISK OF HBeAg-NEGATIVE CHRONIC HEPATITIS B WITH OLDER AGE AT HBeAg SEROCONVERSION
    Fung, J.
    Lai, C. L.
    Wong, D. K. H.
    Yuen, J.
    Yuen, M. F.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S137 - S137
  • [23] Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B
    Rinker, Franziska
    Zimmer, Christine L.
    zu Siederdissen, Christoph Hoener
    Manns, Michael P.
    Kraft, Anke R. M.
    Wedemeyer, Heiner
    Bjoerkstroem, Niklas K.
    Cornberg, Markus
    JOURNAL OF HEPATOLOGY, 2018, 69 (03) : 584 - 593
  • [24] Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants
    Thompson, Alexander J.
    Jackson, Kathy
    Bonanzinga, Sara
    Hall, Sam A. L.
    Hume, Simon
    Burns, Gareth S.
    Sundararajan, Vijaya
    Ratnam, Dilip
    Levy, Miriam T.
    Lubel, John
    Nicoll, Amanda J.
    Strasser, Simone I.
    Sievert, William
    Desmond, Paul V.
    Ngu, Meng C.
    Sinclair, Marie
    Meredith, Christopher
    Matthews, Gail
    Revill, Peter A.
    Littlejohn, Margaret
    Bowden, D. Scott
    Canchola, Jesse A.
    Torres, Jason
    Siew, Philip
    Lau, Jasmin
    La Brot, Benjamin
    Kuchta, Alison
    Visvanathan, Kumar
    HEPATOLOGY COMMUNICATIONS, 2023, 7 (08)
  • [25] HBSAG SEROCOVERSION UNDER LAMIVUDINE IN HBEAG-NEGATIVE CHRONIC HEPATITIS B
    Seven, Gulseren
    Idilman, Ramazan
    Bozkus, Yusuf
    Cinar, Kubilay
    Kabacam, Gokhan
    Yakut, Mustafa
    Bozdayi, A. Mithat
    Yurdaydin, Cihan
    HEPATOLOGY, 2010, 52 (04) : 545A - 546A
  • [26] Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B
    Rizzetto, M
    Tassopoulos, NC
    Goldin, RD
    Esteban, R
    Santantonio, T
    Heathcote, EJ
    Lagget, M
    Taak, NK
    Woessner, MA
    Gardner, SD
    JOURNAL OF HEPATOLOGY, 2005, 42 (02) : 173 - 179
  • [27] Characterization of HBeAg-negative chronic hepatitis B in western Brazilian Amazonia
    Victoria, Flamir da Silva
    Costa de Oliveira, Cintia Mara
    Victoria, Marilu Barbieri
    Victoria, Cristian Barbieri
    Lima Ferreira, Luis Carlos
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2008, 12 (01): : 27 - 37
  • [28] Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B
    Lai, CL
    Shouval, D
    Lok, AS
    Chang, TT
    Cheinquer, H
    Goodman, Z
    DeHertogh, D
    Wilber, R
    Zink, RC
    Cross, A
    Colonno, R
    Fernandes, L
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10): : 1011 - 1020
  • [29] Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon
    Brunetto, MR
    Oliveri, F
    Colombatto, P
    Coco, B
    Ciccorossi, P
    Bonino, F
    JOURNAL OF HEPATOLOGY, 2003, 39 : S164 - S167
  • [30] Predictors of HBsAg Seroclearance in HBeAg-Negative Chronic Hepatitis B Patients
    Kwak, Min-Sun
    Cho, Eun Ju
    Jang, Eun Sun
    Lee, Jeong-Hoon
    Yu, Su Jong
    Kim, Yoon Jun
    Yoon, Jung-Hwan
    Lee, Hyo-Suk
    DIGESTION, 2011, 84 : 23 - 28
12345